Skip to main content
Premium Trial:

Request an Annual Quote

BioCommerce Week s Index to the Diversified Molecular Biology Tool Companies

Harvard Bio and Molecular Devices Fall as BCW Index Climbs 2 Percent

The share price of Harvard Bioscience fell 3.6 percent for the five-day period ending Tuesday, while Molecular Devices fell 2 percent as the only two losers among the 15 companies tracked in the BioCommerce Week Index.

Bruker shares jumped 5.5 percent while Invitrogen climbed 4 percent to lead weekly gainers. Applied Biosystems, which last week introduced a flagship metabolomics product (see cover story in this issue, "As ABI Unveils New Mass Spec for Metabolimics Market, Can It Convince Big Pharma to Buy It?") but declined to detail its ongoing strategic restructuring, climbed 3 percent. Shares climbed for Invitrogen, Bio-Rad, Waters, Thermo Electron, Agilent Technologies, Becton Dickinson, and PerkinElmer — all of whom presented last week at the JPMorgan Healthcare Conference in San Francisco.

Overall, the BCW Index improved 2 percent for the week, after recording a 0.9 percent gain last week. At 34.95, the index is nearing its 19-week high of 35.40 set on Dec. 14.

Overall, the BCW Index outperformed the Dow, which finished up a quarter of a percent for the week; and the S&P 500 and the Nasdaq indices, which finished up three quarters of a percent, while the Amex biotech index improved a half percent and the Amex pharmaceutical index dropped 1.5 percent for the five-day period.

Following is a preliminary schedule of quarterly financial reporting dates for the BCW Index companies:

• Agilent: No date set
• Applied Biosystems: Jan. 27
• Becton Dickinson: Jan. 26
• Beckman Coulter: Jan. 28
• Bio-Rad: Feb. 17
• Bruker BioScience: No date set
• General Electric: Jan. 21
• Harvard Bioscience: No date set
• Invitrogen: No date set
• Molecular Devices: Jan. 31
• Sigma-Aldrich: Feb. 8
• Stratagene: Feb. 7
• Thermo: Feb. 2
• Waters: Jan. 27

 

File Attachments
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.